[go: up one dir, main page]

EP1626981A4 - Dipeptidyl-peptidase protected proteins - Google Patents

Dipeptidyl-peptidase protected proteins

Info

Publication number
EP1626981A4
EP1626981A4 EP04717362A EP04717362A EP1626981A4 EP 1626981 A4 EP1626981 A4 EP 1626981A4 EP 04717362 A EP04717362 A EP 04717362A EP 04717362 A EP04717362 A EP 04717362A EP 1626981 A4 EP1626981 A4 EP 1626981A4
Authority
EP
European Patent Office
Prior art keywords
dipeptidyl
peptidase
protected proteins
proteins
protected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04717362A
Other languages
German (de)
French (fr)
Other versions
EP1626981A2 (en
Inventor
Homayoun Sadeghi
Christopher P Prior
David J Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biorexis Technology Inc
Original Assignee
Biorexis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/378,094 external-priority patent/US7176278B2/en
Application filed by Biorexis Pharmaceutical Corp filed Critical Biorexis Pharmaceutical Corp
Publication of EP1626981A2 publication Critical patent/EP1626981A2/en
Publication of EP1626981A4 publication Critical patent/EP1626981A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP04717362A 2003-03-04 2004-03-04 Dipeptidyl-peptidase protected proteins Withdrawn EP1626981A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/378,094 US7176278B2 (en) 2001-08-30 2003-03-04 Modified transferrin fusion proteins
PCT/US2003/026818 WO2004020405A2 (en) 2002-08-30 2003-08-28 Modified transferrin fusion proteins
PCT/US2004/006462 WO2004078777A2 (en) 2003-03-04 2004-03-04 Dipeptidyl-peptidase protected proteins

Publications (2)

Publication Number Publication Date
EP1626981A2 EP1626981A2 (en) 2006-02-22
EP1626981A4 true EP1626981A4 (en) 2006-11-22

Family

ID=32965093

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04717362A Withdrawn EP1626981A4 (en) 2003-03-04 2004-03-04 Dipeptidyl-peptidase protected proteins

Country Status (2)

Country Link
EP (1) EP1626981A4 (en)
WO (1) WO2004078777A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406490A (en) * 2015-01-23 2017-11-28 诺华股份有限公司 Synthesis APELIN fatty acid conjugates with improved half-life period

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
JP4887139B2 (en) 2003-03-25 2012-02-29 武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CA2535619A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
US8404637B2 (en) 2005-02-11 2013-03-26 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
MX2008002101A (en) 2005-08-12 2008-04-19 Schering Corp Mcp1 fusions.
EP1942898B2 (en) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN102675221A (en) 2005-09-16 2012-09-19 武田药品工业株式会社 Intermediate in method for preparing pyrimidinedione derivative
CN101534846B (en) 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 Glucagon analogs exhibiting physiological solubility and stability
JP5096363B2 (en) 2005-12-16 2012-12-12 ネクター セラピューティックス GLP-1 polymer complex
AU2007227202B2 (en) * 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP2009537812A (en) * 2006-05-15 2009-10-29 デジラブ インコーポレーテッド Biomarker for type 2 diabetes preform and method for detecting the presence or absence of type 2 diabetes preform
CN101501209B (en) 2006-06-21 2013-06-05 百奥勤有限公司 Preparation method of biologically active polypeptide with insulin-stimulating activity
AU2007278994B2 (en) 2006-07-24 2013-08-15 Biorexis Pharmaceutical Corporation Exendin fusion proteins
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8822639B2 (en) 2006-12-12 2014-09-02 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
US7544365B2 (en) * 2006-12-14 2009-06-09 The Hospital For Sick Children TRPV1+ sensory neurons control of β-cells stress and islet inflammation in diabetes
US8669228B2 (en) 2007-01-05 2014-03-11 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
ES2509883T3 (en) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Glucagon antagonists
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
CL2009001424A1 (en) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Glucagon-like peptide; dimer comprising two of said peptides; pharmaceutical composition comprising it; and its use to treat diabetes or induce weight loss.
JP6108659B2 (en) 2008-06-17 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ GIP-based mixed agonist for the treatment of metabolic diseases and obesity
AU2009260301B2 (en) 2008-06-17 2015-09-03 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
MX2011006524A (en) 2008-12-19 2011-08-17 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs.
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
BR112012018585A2 (en) 2010-01-27 2017-01-10 Univ Indiana Res & Tech Corp antagonist-gon agonist glucagon compositions and compositions for the treatment of metabolic disorders and obesity
JP6121323B2 (en) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Peptides of the glucagon superfamily exhibiting nuclear hormone receptor activity
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
CA2802485C (en) 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
CN103119057B (en) 2010-06-24 2016-06-15 印第安纳大学研究及科技有限公司 Insulin prodrug based on amide
EP3208282A1 (en) 2010-11-30 2017-08-23 F. Hoffmann-La Roche AG Low affinity anti transferrin receptor and their use to transfer therapeutic scfv across the blood brain barrier
KR20130132931A (en) 2010-12-22 2013-12-05 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon analogs exhibiting gip receptor activity
US9309301B2 (en) 2011-06-22 2016-04-12 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
HRP20170890T1 (en) 2011-06-22 2017-09-08 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP6324315B2 (en) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon superfamily of peptides exhibiting glucocorticoid receptor activity
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
JP6387008B2 (en) 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Insulin analog dimer
CN105324397B (en) 2013-03-14 2020-01-14 印第安纳大学研究及科技有限公司 Insulin-incretin conjugates
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
CN107001441A (en) 2014-09-24 2017-08-01 印第安纳大学研究及科技有限公司 The lipidization insulin prodrug based on acid amides
CN109053899B (en) * 2017-12-22 2021-11-16 湖南远泰生物技术有限公司 Chimeric antigen receptor containing human transferrin antigen epitope sequence
ES2925678T3 (en) 2018-04-05 2022-10-19 Sun Pharmaceutical Ind Ltd New analogs of GLP-1

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999046283A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP0978565A1 (en) * 1998-01-30 2000-02-09 Suntory Limited Process for producing peptide with the use of accessory peptide
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels
WO2001036643A1 (en) * 1999-11-19 2001-05-25 Transkaryotic Therapies, Inc. Nucleic acid construct for optimized production of products
WO2003016349A1 (en) * 2001-07-19 2003-02-27 Shanghai Hua-Yi Bio-Tech Lab A method of producing glucagon-like peptide 1(glp-1)7-36 and an glp-1 analogue
US20030221201A1 (en) * 2001-08-30 2003-11-27 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0978565A1 (en) * 1998-01-30 2000-02-09 Suntory Limited Process for producing peptide with the use of accessory peptide
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999046283A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels
WO2001036643A1 (en) * 1999-11-19 2001-05-25 Transkaryotic Therapies, Inc. Nucleic acid construct for optimized production of products
WO2003016349A1 (en) * 2001-07-19 2003-02-27 Shanghai Hua-Yi Bio-Tech Lab A method of producing glucagon-like peptide 1(glp-1)7-36 and an glp-1 analogue
EP1408050A1 (en) * 2001-07-19 2004-04-14 Shanghai Hua-Yi Bio-Tech Lab A method of producing glucagon-like peptide 1(glp-1)7-36 and an glp-1 analogue
US20030221201A1 (en) * 2001-08-30 2003-11-27 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ADELHORST K ET AL: "STRUCTURE-ACTIVITY STUDIES OF GLUCAGON-LIKE PEPTIDE-1", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 269, no. 9, 4 March 1994 (1994-03-04), pages 6275 - 6278, XP002045291, ISSN: 0021-9258 *
KAWAI K ET AL: "THE BIOLOGICAL EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AND ITS STRUCTURE-ACTIVITY RELATIONSHIP", BIOMEDICAL RESEARCH, vol. 9, no. SUPPL 3, 1988, pages 213 - 217, XP000574772 *
KIEFFER T J ET AL: "DEGRADATION OF GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE AND TRUNCATED GLUCAGON-LIKE PEPTIDE 1 IN VITRO AND IN VIVO BY DIPEPTIDYL PEPTIDASE IV", ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 136, no. 8, 1 August 1995 (1995-08-01), pages 3585 - 3596, XP000574863, ISSN: 0013-7227 *
KNUDSEN LOTTE B ET AL: "Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 9, 4 May 2000 (2000-05-04), pages 1664 - 1669, XP002201014, ISSN: 0022-2623 *
OHNEDA A ET AL: "THE STRUCTURE-FUNCTION RELATIONSHIP OF GLP-1 RELATED PEPTIDES IN THE ENDOCRINE FUNCTION OF THE CANINE PANCREAS", TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, TOHOKU UNIVERSITY MEDICAL PRESS, SENDAI, JP, vol. 165, no. 3, November 1991 (1991-11-01), pages 209 - 221, XP008014886, ISSN: 0040-8727 *
SVETLANA MOJSOV: "STRUCTURAL REQUIREMENTS FOR BIOLOGICAL ACTIVITY OF GLUCAGON-LIKE PEPTIDE-I", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, MUNKSGAARD, COPENHAGEN, DK, vol. 40, no. 3 / 4, 1 September 1992 (1992-09-01), pages 333 - 343, XP000311244, ISSN: 0367-8377 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406490A (en) * 2015-01-23 2017-11-28 诺华股份有限公司 Synthesis APELIN fatty acid conjugates with improved half-life period

Also Published As

Publication number Publication date
WO2004078777A3 (en) 2006-02-16
WO2004078777A2 (en) 2004-09-16
EP1626981A2 (en) 2006-02-22

Similar Documents

Publication Publication Date Title
EP1626981A4 (en) Dipeptidyl-peptidase protected proteins
EP1633834A4 (en) Improved food-grade-lubricant
PL1714084T3 (en) An owen
GB0324265D0 (en) Peptide
EP1614695A4 (en) Polypeptide
GB0311108D0 (en) Proteins
GB0329664D0 (en) Proteins
GB0304656D0 (en) Proteins
GB0304661D0 (en) Proteins
GB0330036D0 (en) Proteins
GB0305576D0 (en) Proteins
GB0306980D0 (en) Proteins
GB0300503D0 (en) Proteins
GB0318686D0 (en) Proteins
GB0319586D0 (en) Proteins
GB0326291D0 (en) Proteins
GB0326636D0 (en) Proteins
GB0300506D0 (en) Proteins
GB0329145D0 (en) Proteins
GB0304921D0 (en) Proteins
GB0328496D0 (en) Child-net protect
GB0303186D0 (en) Polypeptide
GB0303133D0 (en) Polypeptide
GB0303135D0 (en) Polypeptide
GB0313754D0 (en) Polypeptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050929

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20061025

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOREXIS TECHNOLOGY, INC.

17Q First examination report despatched

Effective date: 20071008

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOREXIS PHARMACEUTICAL CORPORATION

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOREXIS PHARMACEUTICAL CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090207